Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma
Latest Information Update: 26 May 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms SABRseq
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 28 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2018 Status changed from not yet recruiting to recruiting.